|
Synonyms: Feisumei®
beinaglutide is an approved drug (China NMPA (2023))
Compound class:
Peptide or derivative
Comment: Beinaglutide is a glucagon-like peptide-1 (GLP-1) analogue [2-3]. To our knowledge the peptide sequence and/or any anti-proteolytic modifications in beinaglutide have not been disclosed.
|
| No information available. |
Summary of Clinical Use  |
| Beinaglutide was approved by the China National Medical Products Administration (NMPA) in July 2023, as a weight loss drug. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05005741 | The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity. | Phase 4 Interventional | Second Xiangya Hospital of Central South University | ||
| NCT03829891 | Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus | N/A Interventional | Xijing Hospital | ||
| NCT03593668 | Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control | Phase 4 Interventional | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1 | |
